The Strengthening the Screening of Lung Cancer in Europe (SOLACE) initiative, supported by Europe's Beating Cancer Plan, is dedicated to advancing lung cancer screening. This initiative brings together the most extensive pan-European network of respiratory and radiology experts, involving 37 partners from 15 countries. SOLACE aims to enhance equitable access to lung cancer screening by developing targeted recruitment strategies for underrepresented and high-risk populations. Through comprehensive work packages, SOLACE integrates scientific research, pilot studies, and sustainability efforts to bolster regional and national screening efforts across EU member states. CRITICAL RELEVANCE STATEMENT: The SOLACE project aims to facilitate the optimization and implementation of equitable lung cancer screening programs across the heterogeneous healthcare landscape in EU member states. KEY POINTS: The effectiveness of lung cancer screening is supported by both scientific evidence and now increasing legislative support. SOLACE aims to develop, test, and disseminate tools to facilitate the realization of lung cancer screening at both a national and regional level. Previously underrepresented populations in lung cancer screening will be targeted by tailored recruitment strategies. SOLACE forms the first pan-European network of experts poised to drive real-world implementation of lung cancer screening.

Department for Respiratory Diseases Jordanovac University Hospital Centre Zagreb Zagreb Croatia

Department of Biomedical Imaging and Image Guided Therapy Medical University of Vienna Vienna Austria

Department of Diagnostic and Interventional Radiology Heidelberg University Hospital Translational Lung Research Center Heidelberg Germany

Department of Genetics and Clinical Immunology National Institute of Tuberculosis and Lung Diseases Warsaw Poland

Department of Pneumology Lungenklinik Heckeshorn Helios Klinikum Emil von Behring Berlin Germany

Department of Pulmonology University of Debrecen Debrecen Hungary

Department of Radiology Hôpital Cochin AP HP Paris France

Department of Respiratory Medicine Thomayer University Hospital Prague Czech Republic

European Institute for Biomedical Imaging Research Vienna Austria

Faculté de Médecine Université Paris Cité Paris France

Lungs Europe Brussels Belgium

Medical School Berlin Berlin Germany

National Koranyi Institute for Pulmonology Budapest Hungary

School of Medicine University of Zagreb Zagreb Croatia

See more in PubMed

Malvezzi M, Carioli G, Bertuccio P et al (2017) European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann Oncol. 10.1093/annonc/mdx033 PubMed

Malvezzi M, Santucci C, Boffetta P et al (2023) European cancer mortality predictions for the year 2023 with focus on lung cancer. Ann Oncol. 10.1016/j.annonc.2023.01.010 PubMed

Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 10.3322/caac.21660 PubMed

National Lung Screening Trial Research Team (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 10.1056/NEJMoa1102873 PubMed PMC

National Lung Screening Trial Research Team (2013) Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med. 10.1056/NEJMoa1209120 PubMed PMC

de Koning HJ, van der Aalst CM, de Jong PA et al (2020) Reduced lung-cancer mortality with volume CT screening in a randomized trial. N Engl J Med. 10.1056/NEJMoa1911793 PubMed

Pastorino U, Silva M, Sestini S et al (2019) Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol. 10.1093/annonc/mdz117 PubMed PMC

Pastorino U, Boeri M, Sestini S et al (2022) Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial. Ann Oncol. 10.1016/j.annonc.2022.01.008 PubMed

Paci E, Puliti D, Lopes Pegna A et al (2017) Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax. 10.1136/thoraxjnl-2016-209825 PubMed

Infante M, Cavuto S, Lutman FR et al (2015) Long-term follow-up results of the DANTE trial, a randomized study of lung cancer screening with spiral computed tomography. Am J Respir Crit Care Med. 10.1164/rccm.201408-1475OC PubMed

Blanchon T, Bréchot JM, Grenier PA et al (2007) Baseline results of the Depiscan study: a French randomized pilot trial of lung cancer screening comparing low dose CT scan (LDCT) and chest X-ray (CXR). Lung Cancer. 10.1016/j.lungcan.2007.05.009 PubMed

Becker N, Motsch E, Trotter A et al (2020) Lung cancer mortality reduction by LDCT screening-results from the randomized German LUSI trial. Int J Cancer. 10.1002/ijc.32486 PubMed

Wille MM, Dirksen A, Ashraf H et al (2016) Results of the randomized Danish lung cancer screening trial with focus on high-risk profiling. Am J Respir Crit Care Med. 10.1164/rccm.201505-1040OC PubMed

Field JK, Vulkan D, Davies MPA et al (2021) Lung cancer mortality reduction by LDCT screening: UKLS randomised trial results and international meta-analysis. Lancet Reg Health Eur. 10.1016/j.lanepe.2021.100179 PubMed PMC

Ward B, Koziar Vašáková M, Robalo Cordeiro C et al (2023) Important steps towards a big change for lung health: a joint approach by the European Respiratory Society, the European Society of Radiology and their partners to facilitate implementation of the European Union’s new recommendations on lung cancer screening. ERJ Open Res. 10.1183/23120541.00026-2023 PubMed PMC

Kauczor HU, Baird AM, Blum TG et al (2020) ESR/ERS statement paper on lung cancer screening. Eur Respir J. 10.1183/13993003.00506-2019

Van Poppel H, Roobol MJ, Chandran A (2023) Early detection of prostate cancer in the European Union: combining forces with PRAISE-U. Eur Urol. 10.1016/j.eururo.2023.08.002 PubMed

Hejduk K, Vašáková MK, Peterová IČ et al (2022) Design and monitoring of the Czech population pilot programme for lung cancer early detection. Eur Respir J. 10.1183/13993003.congress-2022.3621

Rzyman W, Szurowska E, Adamek M (2019) Implementation of lung cancer screening at the national level: Polish example. Transl Lung Cancer Res. 10.21037/tlcr.2019.03.09 PubMed PMC

Kallavus K, Laisaar KT, Rätsep A et al (2023) National lung cancer screening program feasibility study in Estonia. Interdiscip Cardiovasc Thorac Surg. 10.1093/icvts/ivad041 PubMed PMC

Revel MP, Abdoul H, Chassagnon G et al (2022) Lung cancer screening in French women using low-dose CT and artificial intelligence for detection: the CASCADE study protocol. BMJ Open. 10.1136/bmjopen-2022-067263 PubMed PMC

Vogel-Claussen J, Lasch F, Bollmann BA et al (2022) Design and rationale of the HANSE study: a holistic German lung cancer screening trial using low-dose computed tomography. Rofo. 10.1055/a-1853-8291 PubMed PMC

Kerpel-Fronius A, Monostori Z, Kovacs G et al (2022) Nationwide lung cancer screening with low-dose computed tomography: implementation and first results of the HUNCHEST screening program. Eur Radiol. 10.1007/s00330-022-08589-7 PubMed

Kerpel-Fronius A, Megyesfalvi Z, Markóczy Z et al (2023) HUNCHEST-II contributes to a shift to earlier-stage lung cancer detection: final results of a nationwide screening program. Eur Radiol. 10.1007/s00330-023-10379-8 PubMed

Paci E, Puliti D, Lopes Pegna A et al (2017) Mortality, survival and incidence rates in the ITALUNG randomised lung cancer screening trial. Thorax 72:825–831. 10.1136/thoraxjnl-2016-209825 PubMed

Pastorino U, Silva M, Sestini S et al (2019) Prolonged lung cancer screening reduced 10-year mortality in the MILD trial: new confirmation of lung cancer screening efficacy. Ann Oncol 30:1162–1169. 10.1093/annonc/mdz117 PubMed PMC

Pastorino U, Boeri M, Sestini S et al (2022) Baseline computed tomography screening and blood microRNA predict lung cancer risk and define adequate intervals in the BioMILD trial. Ann Oncol 33:395–405. 10.1016/j.annonc.2022.01.008 PubMed

Milanese G, Silva M, Ledda RE et al (2024) Study rationale and design of the PEOPLHE trial. Radiol Med 129:411–419. 10.1007/s11547-024-01764-4 PubMed PMC